The Island of Bantayan in Northern Cebu in the Philippines watched their country’s boxing hero Manny Pacquiao fight against Floyd Mayweather, Jr. during a live public screening on the island, which brought boundless inspiration to many who were still recovering from the effects of Typhoon Haiyan which struck the Philippines in late 2013.
The public screening on the island was made possible with the effort of a large British life insurance company operating in the country in its bid to bring inspiration to the typhoon survivors. The screening was for the first time held simultaneously in Santa Fe, Bantayan and Madridejos municipalities on Bantayan Island.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7516751-prudential-corporation-asia/
VTech® (www.vtechkids.com), a world leader in age–appropriate and developmental stage–based electronic learning products for children, today announced the availability of its first ever fun camera watch for kids: the Kidizoom® Smartwatch. The world’s first Smartwatch for kids, this innovative, multi–function watch is packed with robust features such as a built–in camera, video and fun photo effects, offering an enriching fun and educational experience in a wearable, kid–friendly, take–anywhere gadget. Leading the way into a new era of wearable technology tailored for children as young as four years old, the Kidizoom Smartwatch is available now at www.vtechkids.com, Amazon.com, Target.com, ToysRUs.com and Walmart.com.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7107952-vtech-kidizoom-kids-smartwatch-wearable-technology/
The Smithsonian's National Museum of American History will open a unique hands-on learning space, the Patrick F. Taylor Foundation Object Project, July 1. Made possible by philanthropist Phyllis Taylor, the 4,000-square-foot space in the museum's new Innovation Wing will focus on “everyday things that changed everything.”
Anchored by an array of individual cases–some overhead, others with visitor-activated sound, light and motion effects–“Object Project” will invite visitors to interact with approximately 250 objects within the 9-by-40-foot sculpture that forms the learning space. The space is divided into four sections: Bicycles, Refrigerators, Ready-to-Wear Clothes and Household Hits, which includes a customized interactive version of “The Price Is Right” game show format licensed from FremantleMedia North America Inc.
To view the Multimedia News Release, go http://www.multivu.com/players/English/7433931-national-museum-of-american-history/
Nearly 12 million men in the U.S. suffer from symptoms related to benign prostatic hyperplasia (BPH), an enlargement of the prostate that can cause issues such as frequent and weak urinary streams and sleep deprivation from getting up repeatedly during the night to urinate. Since traditional BPH therapies such as daily medications and more invasive or surgical procedures often result in unwanted side effects and complications, more than 54 percent of men who would benefit from treating their BPH choose not to do anything1. With today’s national introduction of the FDA-cleared Rezūm® System, NxThera provides urologists and their patients suffering from symptomatic BPH with a new, safe and effective minimally-invasive, office-based treatment option which improves quality of life and preserves sexual function2 – one of the main reasons many men choose to forego medications or more invasive procedures.
“Men suffering from BPH are constantly evaluating the trade-offs between maintaining their current declined quality of life or treating their BPH symptoms and possibly incurring long term side effects,” said Dr. Kia Michel, M.D., a urologist at Comprehensive Urology in Los Angeles who recently performed the procedure as part of a nationally televised segment on prostate health. “Of all the minimally-invasive BPH treatments I’ve performed, Rezūm is the most effective and most versatile treatment available to patients – and the results have been excellent.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7933151-nxthera-rezum-therapy/
Award-winning filmmaker Darryl Roberts takes an unflinching look at the insidious effects of our culture's preoccupation with sex in “America the Beautiful 3: The Sexualization of Our Youth” premiering this fall across the United States.
“America the Beautiful 3: The Sexualization of Our Youth,” is an important yet disconcerting film that both informs and warns viewers that our fixation with sex is adversely affecting our culture, leading to a public health crisis and even worse, the escalation of violence against women and children.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7308551-monte-nido-america-the-beautiful-3-sexualization-youth-darryl-roberts-exposes-obsession/
When a child is diagnosed with cancer, their family is presented with treatment options – often a combination of surgery, radiation and chemotherapy. Radiation and chemotherapy have been used to treat kids’ cancers for more than 50 years and often come with long-term late effects including secondary cancers, heart damage and cognitive issues. Often a child’s best chance at survival is a clinical trial which offers them the newest treatment options available.
In recognition of Childhood Cancer Awareness Month, the St. Baldrick’s Foundation will highlight the critical need to fund lifesaving research and share stories of kids affected by cancer – like Micah, who is alive today because there was a clinical trial available.
To view the multimedia release go to:
https://www.multivu.com/players/English/8284352-st-baldricks-foundation-conquer-childhood-cancers/
At a time when educators and policymakers are placing a high priority on quality early childhood education, Wolf Trap Foundation for the Performing Arts today announced results of a four-year study showing that its arts integration teaching model bolsters young children’s math achievement. Additional resources, including a summary video with classroom demonstrations and the complete research report, may be accessed at http://www.wolftrap.org/stemartsstudy.
Conducted by independent evaluators at the American Institutes for Research (AIR), Findings from the Evaluation of the Wolf Trap Arts in Education Model (the Study) examined the effects of an arts-integrated teaching approach on teachers’ practice and students’ math knowledge.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7224251-wolf-trap-math-achievement/
LivaNova PLC (NASDAQ:LIVN; LSE: LIVN) (“LivaNova” or the “Company”), a market-leading medical technology and innovation company, today recognizes that more than one million people in the United States with drug-resistant epilepsy continue to be treated unsuccessfully with drugs, despite the proven effectiveness of non-drug treatment options. LivaNova’s VNS Therapy®, for example, is a medical device treatment specifically designed for people with drug-resistant epilepsy that is already used by more than 85,000 people around the world.
One in three people with epilepsy has the type that is not well controlled with drugs, called drug-resistant epilepsy. For those people, prescribing more medicine is usually not the most effective option. In fact, research shows that if you haven’t found seizure freedom after your first two drugs, there is a 95 percent chance that no drug or combination of drugs will result in seizure freedom.
“Despite what we know about drug-resistant epilepsy, the majority of people affected by this condition will continue to be prescribed additional medications instead of being evaluated for surgery or seen in a specialized epilepsy facility,” said Jason Richey, president of LivaNova’s U.S. Region and general manager of the Neuromodulation Business Franchise. “This treatment gap means over one million individuals in the U.S. with undertreated epilepsy remain at risk for dangerous side effects of continued seizures, including injury, depression, memory issues and death.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7966451-livanova-vns-therapy-epilepsy/
Things defying gravity and floating away into the sky, people flying and unimaginable objects gliding around have all fascinated us forever. Our television and films have routinely offered us computer-generated treats that seem astonishingly real. While theatre and Live entertainment slowly regains our attention, There is a need to have this same magic of flight recreated on stage. Live. There’s a need to have dancers perform in thin air, of cars ‘driving’ up the sides of buildings, of a superstar ‘flying’ onto the stage in front of our very eyes. And there is a crying need for doing all this with utmost safety.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/71400522-natura-aerial-rigging-flying-safe-and-effortless
http://forthebetter.com.au/
We took the Attention Powered Car on the world's longest inattention road test and we discovered that on average our drivers lost attention at least once every minute.
The Attention Powered Car then headed back to the RAC Driving Centre where further tests were conducted to investigate initial findings from the road trip.
In this new webisode we explore the effects a passenger can have on a driver's attention levels and ways in which passengers might help drivers regain or keep attention behind the wheel.
To see what we've learning about driver inattention, and to get involved with making WA roads safer, go to http://forthebetter.com.au/
Seqirus is now shipping its complete portfolio of seasonal influenza vaccines to customers in the US market for the 2016-2017 season. Seqirus is the only influenza vaccine manufacturer to produce influenza vaccines using both egg-based and cell culture technologies, and the only provider in the US that offers both quadrivalent and trivalent influenza vaccines, as well as the only adjuvanted seasonal influenza vaccine.
Seqirus is now shipping to the US all influenza vaccines in its portfolio, including Fluad™ (Influenza Vaccine, Adjuvanted), Flucelvax Quadrivalent™ (Influenza Vaccine), Afluria® (Influenza Vaccine), and Fluvirin® (Influenza Virus Vaccine) in advance of the peak of influenza season.
“Seqirus is proud to be a major contributor to the prevention and control of influenza by offering healthcare providers and pharmacists with a range of clinically proven, innovative vaccination options that help protect people against the debilitating effects of the disease,” said Brent MacGregor, Senior Vice President, Commercial Operations. “We are committed to being an early and reliable supplier of our influenza vaccines to help ensure that appropriate patients have plenty of time to get their annual immunization.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7902351-seqirus-franchise-shipment/
